Literature DB >> 32998027

An approach for the extract generation and toxicological assessment of tobacco-free 'modern' oral nicotine pouches.

Bishop E1, East N1, Bozhilova S1, Santopietro S1, Smart D1, Taylor M1, Meredith S1, Baxter A1, Breheny D1, Thorne D2, Gaca M1.   

Abstract

Tobacco-free 'modern' oral nicotine pouches (MOPs), are similar in appearance and use to Swedish-style snus, but without tobacco. There are few identified methods to create test samples for toxicologically assessment of MOPs in vitro. In this study we present a simple method for the extraction of pouch material in cell culture media, providing consistent nicotine concentration and easy in vitro assessment. A series of contemporary in vitro screening assays (viability, cell health markers, oxidative stress and genotoxicity) using human oral fibroblasts (HGF) and human lung epithelial cells (H292) were employed. Extracts were generated from LYFT and compared to snus (CRP1.1) and cigarette (1R6F) reference products. MOP and CRP1.1 extracts were generated by incubating one pouch in 20 ml of cell culture media, while 1R6F AqE was prepared by smoking 1 cigarette into 20 ml of cell culture media. 1R6F demonstrated toxicological responses in most assays; CRP1.1 had minimal to moderate effects while MOP demonstrated little or no response in all assays. This study demonstrated the generation of MOPs extracts and their toxicological evaluation using in vitro screening approaches. Future product usage, pharmacokinetics and clinical studies will further substantiate the reduced risk potential of MOPs.
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Cytotoxicity; Genotoxicity; High content screening; In vitro; Nicotine; Oral tobacco

Mesh:

Substances:

Year:  2020        PMID: 32998027     DOI: 10.1016/j.fct.2020.111713

Source DB:  PubMed          Journal:  Food Chem Toxicol        ISSN: 0278-6915            Impact factor:   6.023


  7 in total

1.  Biomarkers of Exposure and Potential Harm in Exclusive Users of Nicotine Pouches and Current, Former, and Never Smokers: Protocol for a Cross-sectional Clinical Study.

Authors:  David Azzopardi; Linsey Ellen Haswell; Justin Frosina; Michael McEwan; Nathan Gale; Jesse Thissen; Filimon Meichanetzidis; George Hardie
Journal:  JMIR Res Protoc       Date:  2022-10-06

2.  Nicotine pouch product awareness, interest and ever use among US adults who smoke, 2021.

Authors:  Mary Hrywna; Nishi J Gonsalves; Cristine D Delnevo; Olivia A Wackowski
Journal:  Tob Control       Date:  2022-02-25       Impact factor: 6.953

3.  A screening approach for the evaluation of tobacco-free 'modern oral' nicotine products using Real Time Cell Analysis.

Authors:  N East; E Bishop; D Breheny; M Gaca; D Thorne
Journal:  Toxicol Rep       Date:  2021-02-25

4.  A Randomised Study to Investigate the Nicotine Pharmacokinetics of Oral Nicotine Pouches and a Combustible Cigarette.

Authors:  Michael McEwan; David Azzopardi; Nathan Gale; Oscar M Camacho; George Hardie; Ian M Fearon; James Murphy
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-12-18       Impact factor: 2.441

5.  A randomised study to assess the nicotine pharmacokinetics of an oral nicotine pouch and two nicotine replacement therapy products.

Authors:  David Azzopardi; James Ebajemito; Michael McEwan; Oscar M Camacho; Jesse Thissen; George Hardie; Richard Voisine; Gavin Mullard; Zvi Cohen; James Murphy
Journal:  Sci Rep       Date:  2022-04-28       Impact factor: 4.996

6.  Use of new approach methodologies (NAMs) to meet regulatory requirements for the assessment of tobacco and other nicotine-containing products.

Authors:  Jacqueline Miller-Holt; Holger P Behrsing; Amy J Clippinger; Carole Hirn; Todd J Stedeford; Andreas O Stucki
Journal:  Front Toxicol       Date:  2022-09-09

7.  Assessment of nicotine delivery and uptake in users of various tobacco/nicotine products.

Authors:  Gerhard Scherer; Janina Mütze; Nikola Pluym; Max Scherer
Journal:  Curr Res Toxicol       Date:  2022-03-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.